Lerkanidipin Actavis (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L‑type calcium channels in the smooth muscle of arterial walls. This blockade prevents calcium entry, causing the vessels to relax and dilate, which decreases peripheral resistance and lowers systemic blood pressure.

The appropriate dose of Lerkanidipin Actavis is determined by the prescribing healthcare professional based on the individual’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. Patients should follow the prescriber’s instructions exactly.

Safety data for lercanidipine in pregnancy and lactation are limited, and the product is generally not recommended unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine class of calcium channel blockers and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may provide smoother blood‑pressure control with a lower incidence of reflex tachycardia, but individual response varies.

Lerkanidipin Actavis tablets should be stored at temperatures below 25 °C in their original blister pack, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep out of reach of children.

The medication is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious adverse events, although rare, include angioedema, severe hypotension, myocardial infarction, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden fainting, chest pain, or jaundice.

Lerkanidipin Actavis is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation, and in those with severe aortic stenosis or unstable angina. Caution is also advised for patients with severe hepatic impairment.